Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 6/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 0.97 |
| ▸ | EGFR | P00533 | 6/20 | 0.75 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.75 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.75 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.75 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.75 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.75 |
| ▸ | ABL1 | P00519 | 1/20 | 0.75 |
| ▸ | PIM1 | P11309 | 1/20 | 0.75 |
| ▸ | PRKACA | P17612 | 1/20 | 0.75 |
| ▸ | LTK | P29376 | 1/20 | 0.75 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.75 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.75 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.75 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.75 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.75 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.75 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.75 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29894633 | 1.00 | ABCG2 (1.00) | ABCG2GAAEGFRERBB2AURKB | |
| SCHEMBL8920 | 0.86 | EGFR (1.00) | ABCG2GAAEGFRERBB2AURKB | |
| SCHEMBL29941271 | 0.86 | EGFR (1.00) | ABCG2GAAEGFRERBB2AURKB | |
| Hydrochloric Acid SCHEMBL8808235 | 0.85 | EGFR (0.90) | ABCG2GAAEGFRERBB2AURKB | |
| Hydrochloric Acid SCHEMBL29394578 | 0.84 | EGFR (0.96) | ABCG2GAAEGFRERBB2AURKB | |
| Hydrochloric Acid SCHEMBL20856873 | 0.84 | EGFR (0.96) | ABCG2GAAEGFRERBB2AURKB | |
| SCHEMBL5569016 | 0.83 | EGFR (0.75) | ABCG2GAAEGFRERBB2AURKB | |
| SCHEMBL5569376 | 0.83 | EGFR (0.81) | ABCG2GAAEGFRERBB2AURKB | |
| SCHEMBL5569041 | 0.83 | EGFR (0.75) | ABCG2GAAEGFRERBB2AURKB | |
| SCHEMBL14027230 | 0.83 | EGFR (0.75) | ABCG2GAAEGFRERBB2AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115124507-B | Quinazoline derivative, preparation method and application thereof | 沈阳药科大学 | 2024-04-30 | — | — | CN | disclosed |
| CN-115124507-A | Quinazoline derivative and preparation method and application thereof | 沈阳药科大学 | 2022-09-30 | — | — | CN | disclosed |
| CN-111303055-B | Quinazoline derivative and preparation method and application thereof | 中国农业科学院兰州畜牧与兽药研究所 | 2021-12-24 | — | — | CN | disclosed |
| CN-111303055-A | Quinazoline derivative and preparation method and application thereof | 中国农业科学院兰州畜牧与兽药研究所 | 2020-06-19 | — | — | CN | disclosed |
| US-7625908-B2 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2009-12-01 | — | — | US | disclosed |
| US-20070244136-A1 | Quinazoline Derivatives | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | disclosed |
| EP-1685116-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2006-08-02 | — | — | EP | disclosed |
| EP-1664029-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005051923-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005026152-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
| US-5616582-A | Use as anticancer agents; e.g. gefitinib | ZENECA LIMITED (GB) | 1997-04-01 | — | — | US | disclosed |
| EP-0566226-B1 | Quinazoline derivatives | ZENECA LTD (GB) | 1995-11-08 | — | — | EP | disclosed |
| US-5457105-A | anticancer use; e.g. 4-(3'-chloro-4'-fluoroanilino)-6,7-dimethoxyquinazoline (gefitinib) | ZENECA LIMITED (GB) | 1995-10-10 | — | — | US | disclosed |
| EP-0566226-A1 | Quinazoline derivatives | ZENECA LIMITED (GB) | 1993-10-20 | — | — | EP | disclosed |
| EP-0310155-A1 | Heteroaryl substituted aminomethyl benzene derivatives, compositions and use | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1989-04-05 | — | — | EP | disclosed |
| EP-0114878-A4 | PHTHALAZINE SUBSTITUTED AMINOMETHYL BENZENE DERIVATIVES, COMPOSITIONS AND USE. | AMERICAN HOSPITAL SUPPLY CORP (US) | 1986-03-18 | — | — | EP | disclosed |
| US-4466965-A | ANTIARRMYTHMIA AGENTS | AMERICAN HOSPITAL SUPPLY CORPORATION (US) | 1984-08-21 | — | — | US | disclosed |
| EP-0114878-A1 | PHTHALAZINE SUBSTITUTED AMINOMETHYL BENZENE DERIVATIVES, COMPOSITIONS AND USE. | AMERICAN HOSPITAL SUPPLY CORP (US) | 1984-08-08 | — | — | EP | disclosed |
| WO-1984000489-A1 | HETEROARYL SUBSTITUTED AMINOMETHYL BENZENE DERIVATIVES, COMPOSITIONS AND USE | AMERICAN HOSPITAL SUPPLY CORP (US) | 1984-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244136-A1 | Quinazoline Derivatives | ERBB2, ABL1, MKI67 | ABCG2 341/4885GAA 2703/4885EGFR 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.